Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban

Am J Physiol Cell Physiol. 2008 Jun;294(6):C1566-75. doi: 10.1152/ajpcell.00367.2007. Epub 2008 Apr 9.

Abstract

Studies have shown that neuronal nitric oxide synthase (nNOS, NOS1) knockout mice (NOS1-/-) have increased or decreased contractility, but consistently have found a slowed rate of intracellular Ca2+ ([Ca2+]i) decline and relengthening. Contraction and [Ca2+]i decline are determined by many factors, one of which is phospholamban (PLB). The purpose of this study is to determine the involvement of PLB in the NOS1-mediated effects. Force-frequency experiments were performed in trabeculae isolated from NOS1-/- and wild-type (WT) mice. We also simultaneously measured Ca2+ transients (Fluo-4) and cell shortening (edge detection) in myocytes isolated from WT, NOS1-/-, and PLB-/- mice. NOS1-/- trabeculae had a blunted force-frequency response and prolonged relaxation. We observed similar effects in myocytes with NOS1 knockout or specific NOS1 inhibition with S-methyl-l-thiocitrulline (SMLT) in WT myocytes (i.e., decreased Ca2+ transient and cell shortening amplitudes and prolonged decline of [Ca2+]i). Alternatively, NOS1 inhibition with SMLT in PLB-/- myocytes had no effect. Acute inhibition of NOS1 with SMLT in WT myocytes also decreased basal PLB serine16 phosphorylation. Furthermore, there was a decreased SR Ca2+ load with NOS1 knockout or inhibition, which is consistent with the negative contractile effects. Perfusion with FeTPPS (peroxynitrite decomposition catalyst) mimicked the effects of NOS1 knockout or inhibition. beta-Adrenergic stimulation restored the slowed [Ca2+]i decline in NOS1-/- myocytes, but a blunted contraction remained, suggesting additional protein target(s). In summary, NOS1 inhibition or knockout leads to decreased contraction and slowed [Ca2+]i decline, and this effect is absent in PLB-/- myocytes. Thus NOS1 signaling modulates PLB serine16 phosphorylation, in part, via peroxynitrite.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Calcium Signaling* / drug effects
  • Calcium-Binding Proteins / deficiency
  • Calcium-Binding Proteins / genetics
  • Calcium-Binding Proteins / metabolism*
  • Citrulline / analogs & derivatives
  • Citrulline / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Isoproterenol / pharmacology
  • Metalloporphyrins / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Contraction* / drug effects
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / metabolism*
  • Nitric Oxide Synthase Type I / antagonists & inhibitors
  • Nitric Oxide Synthase Type I / deficiency
  • Nitric Oxide Synthase Type I / genetics
  • Nitric Oxide Synthase Type I / metabolism*
  • Peroxynitrous Acid / metabolism
  • Phosphorylation
  • Sarcoplasmic Reticulum / metabolism
  • Thiourea / analogs & derivatives
  • Thiourea / pharmacology
  • Time Factors

Substances

  • 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride
  • Adrenergic beta-Agonists
  • Calcium-Binding Proteins
  • Enzyme Inhibitors
  • Metalloporphyrins
  • phospholamban
  • Peroxynitrous Acid
  • Citrulline
  • Nitric Oxide Synthase Type I
  • Nos1 protein, mouse
  • Thiourea
  • Isoproterenol
  • S-methylthiocitrulline